medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2023, Number 4

Next >>

Rev Latin Infect Pediatr 2023; 36 (4)

Papilloma virus

Hernández PM, Vázquez NJA

Language: Spanish
References: 12
Page: 151-154
PDF size: 178.88 Kb.





REFERENCES

  1. Epidemiology and prevention of vaccine-preventable diseases. The 14th edition of the "Pink Book" was published August, 2021.

  2. World Health Organization. Safety oh VPH vaccines. [Accessed February 6, 2023].

  3. Marshall G. Human papillomanvirus. In: Marshall GS, Dennehy PH, Greenberg DP, et al. The vaccine handbook a practical guide for clinicians. 10th ed., 2021.

  4. Who Draft: global strategy towards eliminating cervical cancer as a public health problem.

  5. Olsson SE, Restrepo JA, Reina JC et al. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. Papillomavirus Res. 2020; 10: 100203.

  6. Centers for Disease Control and prevention. HPV vaccine safety and ffectiveness data.

  7. Luxembourg A, Moeller E. 9-Valent human papillomavirus vaccine: a review of the clinical development program. Expert Rev Vaccines. 2017; 16 (11): 1119-1139.

  8. Franceschi S, Clifford GM, Baussano I. Options for design of real-world impact studies of single-dose vaccine schedules. Vaccine. 2018; 36 (32 Pt A): 4816-4822.

  9. Delgado-Sánchez G, Ferreira-Guerrero E. Cobertura de vacunación en niños, niñas y adolescentes en México Salud Pública, 2023. 65 (Supl. 1).

  10. Sankaranarayanan R, Joshi S, Muwonge R et al. Indian HPV vaccine study group. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. Vaccine. 2018; 36 (32 Pt A): 4783-4791.

  11. Kreimer AR, Herrero R, Sampson JN et al. Evidence for single-dose protection by the bivalent HPV vaccine-review of the Costa Rica HPV vaccine trial and future research studies. Vaccine. 2018; 36 (32 Pt A): 4774-4782.

  12. Van Damme P, Bonanni P, Bosch FX, Joura E, Kjaer SK, Meijer CJ et al. Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines. Vaccine. 2016; 34 (6): 757-761.




2020     |     www.medigraphic.com